Symbols

AVTX

Avalo Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 2

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Significant Revenue Decline

EPS Beats Expectation

RSI Overbought

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AVTX

Avalo Therapeutics, Inc.

A biopharmaceutical company that developing treatments for rare and orphan diseases

Industry

Pharmaceutical

Established Date

01/31/2011

Listing Date

11/13/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.avalotx.com

Security Type

Common stock

Office address

1500 Liberty Ridge Drive Suite 321 Wayne Pennsylvania 19087

Business

Introduction

Avalo Therapeutics, Inc., was incorporated in Delaware on January 31, 2011. The company is a clinical-stage biotechnology company fully committed to developing IL-1β-based immune-mediated inflammatory disease treatments. The Company's lead product candidate, abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody (" MAB "), is in Phase 2 clinical trials for hidradenitis suppurativa (" HS "). The company is also exploring more opportunities to make an impact in popular indications where there is a large unmet need.

Company Financials

EPS

AVTX has released its 2025 Q4 earnings. EPS was reported at -0.75, versus the expected -1.25, beating expectations. The chart below visualizes how AVTX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

AVTX has released its 2025 Q4 earnings report, with revenue of 59.00K, reflecting a YoY change of -69.27%, and net profit of -13.72M, showing a YoY change of 61.18%. The Sankey diagram below clearly presents AVTX's revenue sources and cost distribution.